ELVN
Enliven Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$51.67-2.88%
Price as of Jul 20, 2026
ELVN financials
Enliven Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $263.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$263.0K | $0.00 | $0.00 | $0.00 |
| Operating expenses | $119.4M | $104.6M | $83.5M | $38.8M |
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M |
| EBITDA | -$103.4M | -$88.5M | -$71.3M | -$37.4M |
| Basic EPS | $-1.83 | $-1.89 | $-2.01 | $-6.03 |
| Diluted EPS | $-1.83 | $-1.89 | $-2.01 | $-6.03 |
| Balance sheet | ||||
| Cash & equivalents | $98.9M | $124.1M | $100.1M | $75.5M |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M |
| Total liabilities | $16.7M | $15.9M | $26.0M | $160.1M |
| Stockholders’ equity | $459.6M | $309.8M | $245.9M | -$76.8M |
| Total debt | $399.0K | $0.00 | $335.0K | $323.0K |
| Net debt | -$98.5M | -$124.1M | -$99.8M | -$75.2M |
| Cash flow | ||||
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M | -$32.1M |
| Capital expenditure | -$158.0K | -$44.0K | -$149.0K | -$612.0K |
| Free cash flow | -$70.5M | -$73.2M | -$61.4M | -$32.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |